Home › Research › Brain tissue and pathology
Clinical Management of Cerebral Amyloid Angiopathy
Aikaterini Theodorou, Stella Fanouraki, Eleni Bakola, Georgia Papagiannopoulou, Lina Palaiodimou, Maria Eleni Chondrogianni, Maria‐Ioanna Stefanou, Lampis C. Stavrinou et al.. Journal of Clinical Medicine, 2025-06-15
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The vast majority of CAA remains sporadic, with increasing prevalence with age and very frequent coexistence with Alzheimer’s disease. Clinically, CAA can present with spontaneous lobar intracerebral hemorrhage, transient focal neurologic episodes attributed to convexity subarachnoid hemorrhage or cortical superficial siderosis, and progressive cognitive decline leading to dementia. Inflammatory CAA subtype should be recognized early and treated promptly so that better functional outcomes may be achieved. Moreover, genetic and iatrogenic CAA forms are rare, yet increasingly recognized during the last years. Therapeutic management remains challenging for clinicians, especially when markers indicative of higher bleeding risk are present. A targeted therapy does not currently exist. However, various clinical trials are in progress, focusing on offering new promising insights into the disease treatment. This review aims to deepen our understanding of CAA diagnosis and therapeutic approach but also summarizes current evidence on the most uncommon subtypes of this cerebral small-vessel disease.
What this study adds
Evidence grade: Low
This review states that no targeted therapy for cerebral amyloid angiopathy currently exists, and that management remains challenging, especially when markers of higher bleeding risk are present. It notes that various clinical trials are in progress, but reports no treatment that cures or prevents the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Theodorou, A., Fanouraki, S., Bakola, E., Papagiannopoulou, G., Palaiodimou, L., Chondrogianni, M. E., et al. (2025). Clinical Management of Cerebral Amyloid Angiopathy. Journal of Clinical Medicine. https://doi.org/10.3390/jcm14124259
Vancouver
Theodorou A, Fanouraki S, Bakola E, Papagiannopoulou G, Palaiodimou L, Chondrogianni ME, et al. Clinical Management of Cerebral Amyloid Angiopathy. Journal of Clinical Medicine. 2025. doi:10.3390/jcm14124259. PMID: 40566003.
BibTeX
@article{theodorou2025-40566003,
author = {Theodorou, Aikaterini and Fanouraki, Stella and Bakola, Eleni and Papagiannopoulou, Georgia and Palaiodimou, Lina and Chondrogianni, Maria Eleni and Stefanou, Maria‐Ioanna and Stavrinou, Lampis C. and others},
title = {{Clinical Management of Cerebral Amyloid Angiopathy}},
journal = {Journal of Clinical Medicine},
year = {2025},
doi = {10.3390/jcm14124259},
pmid = {40566003},
url = {https://doi.org/10.3390/jcm14124259}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The vast majority of CAA remains sporadic, with increasing prevalence with age and very frequent coexistence with Alzheimer’s disease.
- Clinically, CAA can present with spontaneous lobar intracerebral hemorrhage, transient focal neurologic episodes attributed to convexity subarachnoid hemorrhage or cortical superficial siderosis, and progressive cognitive decline leading to dementia.
- Inflammatory CAA subtype should be recognized early and treated promptly so that better functional outcomes may be achieved.
- Moreover, genetic and iatrogenic CAA forms are rare, yet increasingly recognized during the last years.
- Therapeutic management remains challenging for clinicians, especially when markers indicative of higher bleeding risk are present.
Why it matters
This review states that no targeted therapy for cerebral amyloid angiopathy currently exists, and that management remains challenging, especially when markers of higher bleeding risk are present. It notes that various clinical trials are in progress, but reports no treatment that cures or prevents the disease.
Study details
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Clinical Medicine) |
| Journal's citation record | 2 / 4 | Journal of Clinical Medicine: journal h-index 188 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 11 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 9 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Georgios K. Tsivgoulis: h-index 90 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Tübingen: institution h-index 940 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40566003) |
| Free to read | 2 / 2 | Free to read |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3390/jcm14124259
- PubMed: 40566003
- Original source →
- Free full text: Journal of Clinical Medicine →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Related studies in Brain tissue and pathology from nearby years
Also in Brain tissue and pathology
124 studies in the library are filed under Brain tissue and pathology with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Brain tissue and pathology hub.